Journal of Child and Adolescent Psychopharmacology Developmental Psychopathology and Therapeutics

Journal of Child and Adolescent Psychopharmacology (JCAP) is the premier peer-reviewed journal covering the clinical aspects of treating this patient population with psychotropic medications including side effects and interactions, standard doses, and research on new and existing medications. The Journal includes information on related areas of medical sciences such as advances in developmental pharmacokinetics, developmental neuroscience, metabolism, nutrition, molecular genetics, and more.

Journal of Child and Adolescent Psychopharmacology coverage includes:

• New drugs and treatment strategies including the use of psycho-stimulants, selective serotonin reuptake inhibitors, mood stabilizers, and atypical antipsychotics

• New developments in the diagnosis and treatment of ADHD, anxiety disorders, schizophrenia, autism spectrum disorders, bipolar disorder, eating disorders, along with other disorders

• Reports of common and rare Treatment Emergent Adverse Events (TEAEs) including: hyperprolactinemia, galactorrhea, weight gain/loss, metabolic syndrome, dyslipidemia, switching phenomena, sudden death, and the potential increase of suicide

• Outcomes research

Journal of Child and Adolescent Psychopharmacology is under the editorial leadership of Editor-in-Chief Paul Croarkin, DO, MS, Mayo Clinic Children’s Research Center, and other leading investigators. View the entire editorial board.

Audience: Psychiatrists, developmental psychiatrists, and neuroscientists, among others